The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel.

The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.

A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel.

Methods and compositions for preventing or inhibiting the formation of scars are disclosed. The methods and compositions include a TGF-β inhibitor provided in a delayed release composition.

The present disclosure relates generally to a composition for inhibiting the foreign body response to an implantable device and an implantable device that comprises the composition. The disclosure also relates to methods for preparing a device for implantation in a subject.

A protein-modified PLGA microsphere can be used to construct tissue-engineered nerve. The microspheres are loaded with active substances for treating peripheral nerve injury and are bound to tissue-engineered nerves. It has been shown that the prepared tissue-engineered nerve effectively promotes nerve regeneration after peripheral nerve injury.

Disclosed are a sustained-release injection formulation containing a biodegradable polymer microcapsule that contains a conjugate of poly-L-lactic acid (hereinafter referred to as “PLLA”) filler and hyaluronic acid (hereinafter referred to as “HA”) and contains a PLLA-HA microcapsule, and a method of preparing the same.

A wound dressing is provided, which includes a substrate and a plurality of silver particles. The substrate has a first surface and a second surface which are opposite to each other, and the substrate further includes a plurality of microstructures. A plurality of silver particles is embedded rather in the microstructures or in the gaps between the microstructures, between first surface and the second surface. The wound dressing has a moisture vapor transmission rate being about 4000-20000 g/(m.sup.2*24 hr).

A shape memory polymer hydrogel that is biodegradable, includes antimicrobial agents, and has a tunable drug delivery is used for wound healing internally and externally. The shape memory polymer is synthesized using a combination of hydrophilic precursors that are configured to have two to four functional end groups, with at least one component that has at least three functional groups. The synthesis route provides for a covalently crosslinked thermoset hydrogel. The chemistry can be tuned to provide desired transition temperatures for delivery (e.g. below 37° C.) and desired pore sizes for healing (e.g. 250-500 μm).